BHWM
HAE icon

Bay Harbor Wealth Management’s Haemonetics HAE Stock Holding History

Bay Harbor Wealth Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$750 Buy
10
+5
+100% +$321 ﹤0.01% 969
2026
Q1 		$281 Hold
5
– – ﹤0.01% 1107
2025
Q4 		$400 Buy
5
+2
+67% +$134 ﹤0.01% 938
2025
Q3 		$146 Buy
3
+1
+50% +$62 ﹤0.01% 1102
2025
Q2 		$149 Buy
2
+1
+100% +$66 ﹤0.01% 1017
2025
Q1 		$63 Buy
+1
New +$68 ﹤0.01% 982

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bay Harbor Wealth Management's HAE Position: Q2 2026 in Review

Bay Harbor Wealth Management increased its Haemonetics (HAE) stake by 100% in Q2 2026, buying an estimated $321 and bringing the position to 10 shares worth $750. The position accounts for ﹤0.01% of the portfolio, ranked #969.

Bay Harbor Wealth Management first reported a position in HAE in Q1 2025 and has held it in 6 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Bay Harbor Wealth Management held 10 shares of Haemonetics worth $750 as of Q2 2026.
  • Bay Harbor Wealth Management bought 5 Haemonetics shares in Q2 2026, an estimated $321.
  • Haemonetics made up ﹤0.01% of Bay Harbor Wealth Management's portfolio in Q2 2026, its #969 holding.
  • Bay Harbor Wealth Management first reported a position in Haemonetics in Q1 2025 and has held it in 6 quarters since.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Bay Harbor Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.